Last reviewed · How we verify
NCT03715400: MVR
Mobile Virtual Positive Experiences for Anhedonia
NA trial testing Positive Virtual Reality Training in Anhedonia in 74 participants. Suspended.
1 January 2021
Quick facts
| Lead sponsor | University of California, Los Angeles |
|---|---|
| Phase | NA |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 74 |
| Start date | 1 September 2018 |
| Primary completion | 1 January 2021 |
| Estimated completion | 1 January 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Positive Virtual Reality Training
Conditions studied
- Anhedonia — all drugs for Anhedonia →
- Virtual Reality — all drugs for Virtual Reality →
- Depression — all drugs for Depression →
- Mood Disorders — all drugs for Mood Disorders →
Sponsor
University of California, Los Angeles
Who can join
Adults 18 to 40, any sex, with Anhedonia or Virtual Reality. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anhedonia is a symptom dimension that characterizes many individuals suffering from depression, as well as some types of anxiety, psychosis, and substance use. For the most part, treatments are effective in decreasing negative affect but ineffective in improving anhedonia, with some antidepressant medications even worsening symptoms of anhedonia. Yet anhedonia is a significant marker of poor prognosis as well as suicidal ideation and actual suicide. The development of effective treatments for anhedonia is thus of paramount importance. Advances in neuroscience indicate specific targets that may underlie anhedonia that can be shifted through behavioral training. The investigators have developed such a program and found it to be effective in raising positive affect, especially for depressed or anxious individuals with anhedonia at baseline. To date, this program has been implemented by highly trained clinicians, which have supervised its implementation on a large scale. Moreover, the behavior program is dependent on readily available rewarding experiences, which anhedonia obviously challenges. Furthermore, mechanistic evaluation is impeded by intra¬- and inter-¬individual variability in exposure to rewarding stimuli. Virtual Reality (VR) offsets these barriers by repeated controlled immersion in experiences designed to enhance approach motivation, initial responsiveness to reward attainment, and reward learning. In this current study, the investigators aim to measure clinical outcomes using Virtual Reality-Reward Training (VR-RT).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
How to Treat Depression With Low-Intensity Virtual Reality Interventions: Perspectives on Translating Cognitive Behavioral Techniques Into the Virtual Reality Modality and How to Make Anti-Depressive Use of Virtual Reality-Unique Experiences.
Lindner P, Hamilton W, Miloff A, Carlbring P. · · 2019 · cited 29× · PMID 31736809 · DOI 10.3389/fpsyt.2019.00792
Verify or expand the search:
- PubMed search for NCT03715400
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anhedonia
Currently open trials in the same condition.
- NCT07493369 — Positive Affect Treatment for Spanish-Speaking Individuals · NA · active not recruiting
- NCT07319143 — The Effect of Transcranial Direct Current Stimulation (tDCS) in Improving Emotion Health · NA · recruiting
- NCT07490353 — Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects · Phase 1 · recruiting
- NCT06665620 — Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents · NA · active not recruiting
- NCT06829953 — Get ActivE Study for At-risk Youth · NA · recruiting
Other University of California, Los Angeles trials
Trials by the same sponsor.
- NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
- NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
- NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
- NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
- NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03715400 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
- Last refreshed: 11 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03715400.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing